WHITE PAPER
Fusion Transition:
Why Moving Prostate MRI-US Fusion Procedures to the Office Makes Clinical and Business Sense
.webp)
MRI-US fusion biopsies are now considered the gold standard for men at risk of developing prostate cancer. Providing these procedures in-house allows practices to ensure every patient has access to fusion biopsies, yet many doctors still opt for off-site procedures. With patient outcomes and clinical efficacy at stake, physicians are turning to new fusion biopsy solutions that make it simple and affordable to offer fusion in the office setting.
Download this new white paper to learn how moving fusion biopsies in-house can:
Significantly increase prostate cancer detection rates
Simplify patient scheduling and increase practice efficiency
Build new revenue streams to optimize practice profitability
MRI-US Fusion: The Key to Accelerating Prostate Cancer Detection
MRI-Guided
Standard Biopsy
The Lancet Vol 389 February 25, 2017 (PROMIS Study).
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32401-1/fulltext
In the PROMIS study,³ a multi-center paired cohort comparing MRI-targeted biopsies and standard biopsies to template mapping biopsy of the prostate, MRI-guidance delivered 93% sensitivity in detecting clinically significant high-grade cancer (Gleason >4+3), while standard biopsies only detected 48%.
END-TO-END PRACTICE OPTIMIZATIONS
Enhancing Financial, Logistical & Clinical Outcomes
Explore insider insights in the white paper to learn how in-office fusion drives measurable improvements in:
Scheduling efficiency
Access to fusion
Practice reimbursements
Treatment surveillance
Clinical outcomes
Patient satisfaction